-
Product Insights
Bone Marrow Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Bone Marrow Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Bone Marrow Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Male Hypogonadism – Drugs In Development, 2023
Global Markets Direct’s, ‘Male Hypogonadism - Drugs In Development, 2023’, provides an overview of the Male Hypogonadism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Male Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Germ Cell Tumors – Drugs In Development, 2023
Global Markets Direct’s, ‘Germ Cell Tumors - Drugs In Development, 2023’, provides an overview of the Germ Cell Tumors pipeline landscape. The report provides comprehensive information on the therapeutics under development for Germ Cell Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Bronchitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Bronchitis - Drugs In Development, 2023’, provides an overview of the Bronchitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s MK-4830
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewNet Present Value Model: Mereo Biopharma Group Plc’s Etigilimab
Empower your strategies with our Net Present Value Model: Mereo Biopharma Group Plc's Etigilimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brincidofovir in Polyomavirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brincidofovir in Polyomavirus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brincidofovir in Polyomavirus Infections Drug Details: Brincidofovir (Tembexa) is an alkoxyalkyl ester...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADG-126 in Metastatic Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ADG-126 in Metastatic Uveal Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ADG-126 in Metastatic Uveal Melanoma Drug Details: ADG-126 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cadonilimab in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cadonilimab in Colorectal Cancer Drug Details: Cardinalizumab (Ketanil) is a bi-specific antibody...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Etigilimab in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Etigilimab in Sarcomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Etigilimab in Sarcomas Drug Details: Etigilimab (OMP-313M32) is under development for the...